Accelerating Enrollment for a Phase II IPF Study



Phase II clinical study for patients with IPF.
- Date October 2020
- Therapeutic Area Idiopathic Pulmonary Fibrosis
- Study Type Phase II | Rescue
- Challenges COVID-19 Pandemic | High patient burden (1-year-long commitment)
Responsum was brought in to boost enrollment in the US market quickly, as existing efforts had failed. The campaign has been slow in the US. 20+ randomized patients needed quickly.
Strategy and results:
Leveraging our 3.6K+ member pulmonary fibrosis community, we launched a targeted campaign centered on clinical trial education, streamlined phone screening, and a personalized email drip campaign designed to align with participants’ preferences and demographics.
52 patients were referred successfully, 13 screened, and 8 randomized. All from our IPF community.






“We got 300% grown result from being at a coworking space compared to working from home/coffee shops. We’re far more settled and happy in this company!”